— Bob Azelby is leaving his position as president and CEO of Elieum Therapeutics and stepping down from its board. General counsel Jim Bucher and Erin Lavelle, chief operating officer… Read More
Shares of Eliem Therapeutics fell more than 50% Monday after the company reported disappointing clinical data. Its compound to treat pain, ETX-810, failed to show a benefit over placebo in… Read More
Eliem Therapeutics, a clinical stage biotech company generating therapies for pain, depression and other nervous-system related conditions, has filed to go public via an IPO. The company’s filing with the… Read More
Alder BioPharmaceuticals has raised $170 million in a stock offering and is ramping up operations after filing an FDA application for eptinezumab, a therapy for patients with chronic migraines. Alder… Read More
In one of two recent Microsoft-to-Amazon moves, Brian Schultz, who has worked on-and-off at Microsoft since 1999, is now working on Amazon Web Services. According to his LinkedIn profile, Schultz is… Read More